Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
FATE 
Fate Therapeutics Inc (FATE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: FATE (3-star) is a STRONG-BUY. BUY since 9 days. Simulated Profits (23.97%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $4.45
1 Year Target Price $4.45
| 3 | Strong Buy |
| 2 | Buy |
| 7 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 85.23% | Avg. Invested days 29 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 160.31M USD | Price to earnings Ratio - | 1Y Target Price 4.45 |
Price to earnings Ratio - | 1Y Target Price 4.45 | ||
Volume (30-day avg) 12 | Beta 2.35 | 52 Weeks Range 0.66 - 3.50 | Updated Date 10/13/2025 |
52 Weeks Range 0.66 - 3.50 | Updated Date 10/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.46 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1938.54% |
Management Effectiveness
Return on Assets (TTM) -24.66% | Return on Equity (TTM) -52.11% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -1947067 | Price to Sales(TTM) 18.93 |
Enterprise Value -1947067 | Price to Sales(TTM) 18.93 | ||
Enterprise Value to Revenue 20.39 | Enterprise Value to EBITDA -2.59 | Shares Outstanding 115329697 | Shares Floating 100797002 |
Shares Outstanding 115329697 | Shares Floating 100797002 | ||
Percent Insiders 1.71 | Percent Institutions 78.58 |
Upturn AI SWOT
Fate Therapeutics Inc
Company Overview
History and Background
Fate Therapeutics was founded in 2007 and is focused on developing cell-based cancer immunotherapies using induced pluripotent stem cells (iPSCs). Its goal is to create off-the-shelf, allogeneic cell therapies.
Core Business Areas
- iPSC-Derived Cell Therapies: Developing off-the-shelf NK cell and T-cell cancer immunotherapies derived from iPSCs. This includes programs targeting hematologic malignancies and solid tumors.
Leadership and Structure
Scott Wolchko serves as the President and CEO. The company has a board of directors and various departments focused on research, development, manufacturing, and clinical operations.
Top Products and Market Share
Key Offerings
- FT596 (off-the-shelf CAR NK cell therapy): An investigational off-the-shelf, iPSC-derived CAR NK cell therapy targeting CD19-expressing B-cell malignancies. The company is focused on progressing the clinical trials. Competitors include autologous CAR-T therapies from companies such as Novartis (NVS) and Gilead (GILD).
- FT510 (off-the-shelf NK cell therapy): An investigational off-the-shelf, iPSC-derived NK cell therapy. Competitors include other NK cell therapy developers such as Nkarta (NKTX) and Century Therapeutics (IPSC).
Market Dynamics
Industry Overview
The cell therapy market is rapidly growing, driven by advancements in immunotherapy and gene editing. The industry is characterized by intense competition and high R&D costs.
Positioning
Fate Therapeutics aims to differentiate itself with its iPSC-derived, off-the-shelf approach, providing potential advantages in scalability and accessibility compared to autologous cell therapies.
Total Addressable Market (TAM)
The total addressable market for cell therapies is estimated to reach tens of billions of dollars. Fate Therapeutics is positioned to capture a share of this market with its off-the-shelf technology if clinical trials are successful.
Upturn SWOT Analysis
Strengths
- iPSC-derived platform for scalable production
- Off-the-shelf approach for broader patient access
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- Clinical trial risks and uncertainties
- High R&D expenses
- Dependence on regulatory approvals
- Cash Burn
Opportunities
- Expanding pipeline with new cell therapy candidates
- Partnerships with pharmaceutical companies
- Advancements in gene editing technologies
- Addressing unmet medical needs in oncology
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Unfavorable clinical trial results
- Ethical concerns surrounding cell therapies
Competitors and Market Share
Key Competitors
- GILD
- NVS
- NKTX
- IPSC
Competitive Landscape
Fate Therapeutics' competitive advantage lies in its iPSC-derived, off-the-shelf approach. However, it faces competition from companies with established autologous CAR-T therapies and other NK cell therapy developers.
Growth Trajectory and Initiatives
Historical Growth: Fate Therapeutics' growth has been driven by advancements in its iPSC platform and progress in clinical trials.
Future Projections: Future growth depends on the success of its clinical programs and potential partnerships.
Recent Initiatives: Recent initiatives include advancing clinical trials for FT596 and FT510, and exploring new cell therapy targets.
Summary
Fate Therapeutics is a clinical-stage biopharmaceutical company with a novel iPSC-derived cell therapy platform. The company faces risks inherent in drug development, but has the potential to disrupt the cancer immunotherapy market. Success depends on positive clinical trial results and regulatory approvals. Its cash burn is high and must be monitored.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a financial advisor. Market share data is based on estimations and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Fate Therapeutics Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2013-10-01 | President, CEO & Director Dr. Bahram Valamehr M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 181 | Website https://www.fatetherapeutics.com |
Full time employees 181 | Website https://www.fatetherapeutics.com | ||
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.